Anti-Alpha-Synuclein, ASyO5, Mouse, Monoclonal, Oligomer specific

Immunogen

Synthetic peptide derived from human Alpha-Synuclein, amino acids 111-125.

Host

Mouse

Clonality

Monoclonal

Subclass/isotype

IgG1, (clone number 2.4)

Purity

Affinity purified in PBS pH 7.4.

Format

Lyophilized

Quantity

50 µg

Reconstitution

For reconstitution add 50 µl of sterile water.

Storage

For short time storage add sodium azide and store at +4°C.
For long time storage store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please, remember to spin tubes briefly prior to opening them to avoid any losses that might occur from lyophilized material adhering to the cap or sides of the tubes.

Tested applications

Dot blot (Dot), ELISA (ELISA), Immunohistochemistry (IHC)

Recommended Dilution

1-2 ug/ml (Dot), 2-4 ug/ml (ELISA capture), 10 ug/ml (IHC)

Expected | apparent MW

14 kDa

Confirmed Reactivity

Human

Not reactive in

No confirmed exceptions from predicted reactivity are currently known.

Application examples

Dot Blot

Dot blot reaction of the binding capacity of ASyO5 to fibrils, monomers and oligomers. Equal amounts of each sample were spotted on a nitrocellulose membrane and then dried. The membrane was blocked with 5% non-fat milk before incubated for 1 h with anti-ASyO5 (25nM) and then with secondary antibody, anti-mouse HRP-conjugated (1:1500). The membrane was washed with PBS containing 0.25% Tween-20 before detection using ECL prime (GE Healthcare).

Immunolocalization

Tissue sections from the human PD midbrain, substantia nigra, were de-waxed and rehydrated in ethanol and then incubated with ASyO5 at RT for 1h. The immunoreactivity was detected with the anti-mouse Peroxidase Reagent Kit (ImmPRESS, Vector Laboratories, Inc.) and then developed using the ImmPACT AEC Peroxidase Substrate kit (Vector Laboratories, Inc.).

Additional information

This antibody is specific to oligomers in ELISA as a capture antibody. For specific details, please check: Brännström et al. (2014). A Generic Method for Design of Oligomer-Specific Antibodies. PLoS ONE. DOI: 10.1371/journal.pone.0090857.

Related products

Available antibodies targeting Alpha-Synuclein

Background

Alpha-synuclein is normally an unstructured soluble protein that can aggregate to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy-bodies, and multiple system atrophy. In analogy to many other amyloid associated disorders, alpha-synuclein may also form oligomeric assemblies. These small and soluble forms have been suggested to exert a stronger tissue damaging effect as compared to the monomeric and fibrillar counterpart. Using a recently developed technique a monoclonal oligomer-specific antibody has been designed.

Product citations

Wu et al. (2017). The critical role of Nramp1 in degrading α-synuclein oligomers in microglia under iron overload condition. Neurobiol Dis. 2017 Aug;104:61-72. doi: 10.1016/j.nbd.2017.05.001.(human, mouse, immunolocalization)

Svarcbahs et al. (2016). Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain. J Neurosci. 2016 Dec 7;36(49):12485-12497.

Brännström et al. (2014). A Generic Method for Design of Oligomer-Specific Antibodies. PLoS ONE. DOI: 10.1371/journal.pone.0090857.